Cooperative Agreement 7200AA23CA00020

This $7,105,240 Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), will develop an HIV vaccine regimen that elicits both broadly neutralizing antibodies and high-quality T-cell responses. The research program, named OPTI-FLIP, combines investigations into cooperative antibody and T-cell immunity, as well as innovative strategies for generating follicular T cells and cytotoxic T...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to enhance HIV prevention through a vaccine approach that promotes durable immunity. The $737,761 award will fund research to induce robust CD4 T follicular helper (Tfh) cells, which are essential for vigorous B cell activity within germinal centers and the production of persistent antibodies. The research will examine...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to develop an HIV vaccine. The $228,825 award, effective August 9, 2024 through June 30, 2026, aims to synergize neutralizing and non-neutralizing antibody targets at the HIV/SIV viral spike apex. The research will 1) design and validate a vaccine immunogen focused on the V2B neutralization epitope, and 2)...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $176,063 to the University of Hawaii to conduct research on designing and testing novel HIV vaccine immunogens. The goal is to develop immunogens that can guide the evolution of the VRC01 broadly neutralizing antibody lineage towards a mature phenotype capable of producing antibodies that can neutralize diverse HIV...

This $2,688,880 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to evaluate the safety and therapeutic potential of a novel strategy towards a cure for HIV infection. The key research objectives include: Comprehensively testing the effects of IL-15/IL-15RA therapy combined with TGF-beta pathway blockade on different T and NK cell subsets during chronic SIV...

This federal Project Grant award of $905,998 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to evaluate the safety, immunogenicity, and efficacy of an attenuated Mycobacterium tuberculosis (MTB) vaccine candidate in the setting of HIV co-infection. The research will be conducted by the Texas Biomedical Research Institute, doing business as the Southwest Foundation For Biomedical...

The federal Project Grant award R01AI181671 for $650,156.00, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development and evaluation of a multi-epitope protease cleavage sites (MEPCS) vaccine for protecting against SIV rectal transmission. The award aims to comparatively evaluate the effectiveness of a cold-chain friendly and long-term stable MEPCS-mRNA-LNP vaccine versus an...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $431,712 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to The Regents of the University of California, San Francisco (UCSF) to improve HIV testing among children under five in rural Uganda. The key objectives are to determine barriers and facilitators to pediatric HIV testing, and pilot a traditional healer-facilitated HIV testing intervention for children 18 months to 5 years old. UCSF will...

This $194,616 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) is funding research to develop virus-like particles (VLPs) for a novel HIV-1 cure strategy. The project aims to use VLPs to deliver the HIV-1 Tat protein as a latency reversing agent (the "shock") and then target the reactivated cells for elimination using adeno-associated virus (AAV) vectors expressing broadly...

This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $183,602 to The University of North Texas Health Science Center at Fort Worth to construct an HIV-1/SIV chimeric virus, termed HSIVNEF, that can replicate in simian cells. The research aims to develop an improved simian model for studying AIDS pathogenesis and evaluating vaccine and therapeutic candidates....